The company is leveraging success with its COVID-19 tests to position itself better for a post-pandemic world.
Compare FLGT Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Fulgent Genetics, Inc.
News & Analysis: Fulgent Genetics, Inc.
Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company.
With this particular acquisition, Medallia shareholders are being cashed out. Here are two ideas for that cash.
The pandemic isn't over yet.
The company is about to shock Wall Street.
Hedging against COVID-19 could prove to be crucial in keeping your portfolio safe.
Spectacular quarterly results were not enough to satisfy investors' appetites.
FLGT earnings call for the period ending June 30, 2021.
The stock has traded with the ebbs and flows of COVID cases, but its testing has consistently delivered for its impressive list of customers.
Few companies had bigger tailwinds from COVID-19. What comes next could be even more exciting.